March 2, 2026 — Leads & Copy —
Quanterix Corporation (NASDAQ: QTRX) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company, which focuses on scientific discovery through ultra-sensitive biomarker detection, reported revenue of $43.9 million for the fourth quarter, a 25% increase compared to the prior year’s $35.2 million.
For the full year 2025, Quanterix posted revenue of $138.9 million, a 1% increase from $137.4 million in the previous year.
Everett Cunningham, President & CEO of Quanterix, said he is thrilled to join the company at a time when it is well-positioned for long-term growth. He added that during the fourth quarter, Quanterix exceeded revenue expectations and continued to move closer to profitability, achieving key milestones in its Alzheimer’s Diagnostics business.
Cunningham stated that with most major integration milestones complete, the company’s focus is now on driving consistent profitable revenue growth and achieving cash flow breakeven performance in 2026. His immediate focus involves spending time with the Quanterix team, customers, shareholders, and partners to evaluate the company’s strategy and future potential, ensuring the resources, support, and capabilities to deliver on operational priorities.
Quanterix reported a GAAP gross margin of 45.7% for the fourth quarter, compared to 63.0% in the prior year. The adjusted gross margin (non-GAAP) was 50.0% compared to 57.7% in the prior year. The adjusted EBITDA (non-GAAP) loss was $7.9 million, compared to a loss of $5.9 million in the prior year. The company ended the fourth quarter with $121.6 million in cash, cash equivalents, marketable securities, and restricted cash.
For the full year, the GAAP gross margin was 46.8%, compared to 60.5% in the prior year, and the adjusted gross margin (non-GAAP) was 47.3% compared to 54.6% in the prior year. The adjusted EBITDA (non-GAAP) loss was $44.9 million, compared to a loss of $23.6 million in the prior year. Adjusted cash usage, after accounting for one-time deal and restructuring costs, was $30.9 million in 2025 compared to $32.2 million in the prior year.
In January 2026, Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for its multi-analyte algorithmic blood test for Alzheimer’s disease. The Centers for Medicare & Medicaid Services (CMS) established a reimbursement rate of $897 for Quanterix’s LucentAD Complete test.
The company announced it has implemented $74 million of cost savings related to its Akoya transaction and expects to capture its remaining cost synergies by the end of the first quarter of 2026, with 94% of the integration milestones now complete. In 2025, Quanterix launched 13 new assays, including two new Simoa tau assays, pTau 205 and pTau 212, and two new Phenocode Discovery panels in Q4 2025 – Metabolism Spike In Panel and Mouse Neurology Panel.
Quanterix is issuing its initial guidance for 2026, expecting revenues of $169 to $174 million, a GAAP gross margin of 45-49%, and an adjusted gross margin (non-GAAP) of 49% to 53%. The company expects to achieve cash flow breakeven performance in the second half of 2026 and exit the year with approximately $100 million in cash and no debt.
Quanterix will host a conference call on March 2, 2026, at 4:30 PM E.T. Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website.
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,439 installed instruments.
Source: Quanterix
